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incentives, reciprocity, and indirect/direct ﬁnancial incentives for
organ donation. To elucidate the values and preferences of the
public regarding organ procurement systems. METHODS: Con-
cepts and theories of altruism identiﬁed in economic literature
are applied to transplantation. This theoretical overview has
been extended by a comprehensive literature search that identi-
ﬁed 48 international surveys and studies which empirically
explore public attitudes towards human organ donation and
ﬁnancial incentives for deceased and living organ donation.
RESULTS: The identiﬁcation of a series of alternative approaches
of human organ donation reveals that donation based on altru-
ism alone may have become too costly for a community as
voluntary donations have remained almost ﬂat during the last
decades, while the number of patients on waiting lists have
attentively increased. The value of these lost lives seem to be
evaluated lower than keeping altruism as the main principle of
donating organs. As a cosequence some stakeholders have been
questioned that altruism is enough to meet increasing demand for
organs and propose supplementing the principle of giving by
introduction of ﬁnancial incentives for donors or fully replacing
it by pricing mechanism. For a community choosing any of these
donation approaches it is especially important not only to be
attracted by some appeal any proposal may offer but to further
investigate the implicit assumptions and their potential limita-
tions the donation policies are based on. While it is estimated
that the debates on the ethics of organ donation are well under-
stood by those involved in organ procurement and donation, the
values and preferences of the public regarding organ procure-
ment systems under scientiﬁc discussion are not that well known
and therefore have to be elucidated. Though, 48 international
surveys and studies to investigate public attitudes towards
human organ donation and ﬁnancial incentives for deceased and
living organ donation have been identiﬁed in a comprehensive
literature search, it is revealed that it is unknown whether
e.g., the opportunity for trading one’s organ(s) is determined by
community values. CONCLUSIONS: Transplant decision-
makers should rather than imposing their values to the commu-
nity, instead should answer to community values. It is necessary
to identify the community preferences and values with respect to
the organ procurement proposals and prepare on this informed
basis an adequate donation policy which is in line with commu-
nity values. The process of consulting the community may reveal
that individuals are altruistically motivated and would donate
their organs after death, and that all is missing is mutual trust. An
informed ethical debate and dialogue between members of the
transplant expert community and the public is needed to decide
which organ procurement approach best reﬂect the communities’
shared values.
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OBJECTIVES: Fibromyalgia syndrome (FMS) is a painful con-
dition which deteriorates patient’s functioning and might impair
cognitive function. The goal of this analysis was to screen cog-
nitive function of patients with FMS. METHODS: We surveyed
consecutive patients with a diagnosis of FMS according to ACR
criteria. Cognitive function was screened with the MiniMental
State Examiantion (MMSE). Medical history, level of pain (Short
Form-McGill Pain Questionnaire) and symptoms of depression
and anxiety (Raskin and COVI scales, respectively) were also
recorded. MMSE scoring was adjusted by age, sex, pain intensity
and COVI and Raskin scoring by linear regression modeling.
RESULTS: Forty-six patients [mean SD; 50.8  10.1 years old
(90.9% female)] with FMS were enrolled in the study. Patients
had FMS for 1.9  2.6 years. Most patients (60.3%) complained
of severe pain (above 70) with a mean present pain intensity of
2.6  1.0 (range 0–5) and a mean last-week average pain of
70.8  16.0 mm (range: 0–100). Painful FMS subject’s average
unadjusted MMSE score was 26.7  3.1 pts, with 15.2% of
patients with a scoring 24 pts (possible cognitive deﬁcit). After
adjusting, average MMSE scoring was 26.7  1.2 pts, with 5.1%
of subjects scoring 24 pts, which is considerable higher than in
sex and age matched general population (0.05%). Frequency of
possible cognitive deﬁcit was independent of concomitant
medications, pain severity, age and sex. In the bivariate analysis,
frequency of subjects with depressive or anxiety symptoms (as
ranked by RASKIN and COVI scales, respectively) were numeri-
cally higher in patients with MMSE 24, but statistically not
signiﬁcant (p = 0.235 and 0.225, respectively). CONCLUSIONS:
Cognitive impairment as assessed by the MMSE may be a mean-
ingful clinically ﬁnding in patients with Fibromyalgia. Further
investigation in large samples of FMS patients should be carried
out to explore to what extent cognitive function is impaired in
these subjects.
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OBJECTIVES: Although cDXA is considered the gold standard
for diagnosis of osteoporosis, it requires massive and radiation-
protection-intensive radiological settings. Peripheral DXA mea-
surements would be more practically convenient but their results
do not correlate very well with that of cDXA. Against this
background, DXL was developed. It combines peripheral DXA
measurement with a laser-deﬁned region of interest to correct for
artefacts. In order to clarify the diagnostic accuracy and hereby
the clinical utility, a literature overview was undertaken.
METHODS: The systematic literature search covered Medline,
Embase (including Embase Alert) and the Cochrane Library.
Diagnostic studies comparing the diagnostic accuracy of DXL
against cDXA were identiﬁed and their methodological qualities
assessed using the QUADAS instrument. Furthermore abstract
publications were included if they contained sufﬁcient data. It
was planned to calculate pooled estimates of diagnostic accuracy
parameters on the condition that the studies yielded sufﬁciently
high quality data. RESULTS: Six published trials and two
meeting abstracts were appraised. Owing to diversity in the study
subjects’ origins, variable risk factor constellations and the inho-
mogeneity of the reference method (i.e. cDXA model, measure-
ment site, execution procedures and reference population)
employed in the studies, we decided on not performing meta-
analysis. One abstract publication was invalid for calculating
diagnostic accuracy statistics due to data inconsistency. The
ranges of sensitivities (54.6%–100.0%), speciﬁcities (64.3%–
86.0%), positive predictive values (33%–82%), negative predic-
tive values (73%–100%), positive likelihood ratios (2.20–6.25),
negative likelihood ratios (0.00–0.54) and diagnostic odds ratios
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(6.47-inﬁnity) were calculated or conﬁrmed and compared
among the studies. Variability was explained by the use of
different cut-offs, different reference methods (e.g. cDXA’s
measurement sites) and different subject’s populations.
CONCLUSIONS: Although the results of some studies appear
promising; further reﬁnement of indications, population-speciﬁc
reference databases and studies to determine valid cut-off are
needed before the technology can be successfully introduced into
routine care.
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OBJECTIVES: The objective of this study was to compare efﬁ-
cacy and safety of leﬂunomide with biological antirheumatic
drugs (adalimumab, etanercept, inﬂiximab, rituximab, anakinra)
in active rheumatoid arthritis. METHODS: Comparison was
based on systematic review, carried out according to guidelines
published by the Cochrane Collaboration and Agency for Tech-
nology Assessment in Poland. The most important medical data-
bases (EMBASE, MEDLINE, CENTRAL) were searched. Two
reviewers independently selected trials, assessed trial quality and
extracted data. No head to head trials were identiﬁed so indirect
comparison using Bucher’s method was performed. RESULTS:
The results of 33 randomized controlled trials were included in
indirect comparison. Leﬂunomide was shown to have better
ACR20 response than anakinra (RR = 1.44 [1.14; 1.81]) but no
signiﬁcant differences in ACR response were found in compari-
sons with other drugs. Comparisons of HAQ disability scores
indicate than leﬂunomide reduces disability better than adali-
mumab (WMD = -0.15; [-0.29; -0.01]), inﬂiximab (WMD =
-0.35 [-0.50; -0.20]), anakinra (WMD = -0.47 [-0.69; -0.25]),
rituximab (WMD = -0.38 [-0.59; -0.17]), but not etanercept
(WMD = -0.18 [-0.37; 0.01]). Radiographic improvement was
better in comparison with anakinra (WMD = -2.99 [-5.82;
-0.16]) and rituximab (WMD = -4.05 [-6.67; -1.43]) whereas
worse in comparison with adalimumab (WMD = 2.67 [0.87;
4.47]), etanercept (WMD = 1.75 [0.01; 3.49]) and inﬂiximab
(WMD = 2.06 [0.42; 3.70]). Leﬂunomid signiﬁcantly increases
the risk of treatment discontinuation due to the adverse events in
comparison with etanercept (RR = 3.50 [1.55; 7.88]). No signiﬁ-
cant differences in safety outcomes were noted between leﬂuno-
mid and other drugs. CONCLUSIONS: Indirect comparisons
indicate similar efﬁcacy of leﬂunomid, adalimumab, etanercept,
inﬂiximab or rituximab. Leﬂunomide seems to be more effective
than anakinra. Safety proﬁle of leﬂunomide is worse in compari-
son with etanercept, whereas in comparison with other analyzed
drugs no differences were found.
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OBJECTIVES: To estimate the cost-effectiveness relationship of
leﬂunomide compared to inﬂiximab, etanercept and adalimumab
for the treatment of patients with rheumatoid arthritis (RA) with
suboptimal response despite methotrexate (MTX) monotherapy.
METHODS: Time horizon was 24 weeks. Efﬁcacy data was
obtained from systematic review of published literature. The
model compares four groups: leﬂunomide, inﬂiximab, etanercept
and adalimumab, all in combination with MTX, under the per-
spective of Public Health Sector in Mexico. We included direct
costs of medications during 24 weeks and costs associated with
therapeutic failure due to adverse events or lack of efﬁcacy. In
those cases, we calculated initial treatment costs during 8 weeks,
and after treatment changed, it was estimated an average cost of
biological therapy for the 16 remaining weeks. The effectiveness
measure was the response rate according to the American College
of Rheumatology criteria (ACR). The analysis was conducted
using Tree Age Pro Suit 2006. RESULTS: The proportion of
patients reaching an ACR20 response was 50% for leﬂunomide,
53% for inﬂiximab, 61.6% for adalimumab and 67.9% for
etanercept. The expected costs of 24 weeks of treatment were
€891.2, €4274.5, €5054.5 and €4072.3 for leﬂunomide, inﬂix-
imab, adalimumab and etanercept, respectively. The cost per
patient with ACR20 improvement was €1781.8 for leﬂunomide,
€8205.8 for adalimumab, €8069.9 for inﬂiximab and €5996.7
for etanercept. The average cost per patient reaching an ACR50
or ACR70 response was also much lower for leﬂunomide
(€ 3,248.7, €8,999.2) than for the biological agents: etanercept
(€ 9492.6, €23,424.6), adalimumab (€ 12,290.4, €23,646.5),
inﬂiximab (€14,726.1, €40,349.5). CONCLUSIONS: Leﬂuno-
mide added to MTX is a cost-effective strategy compared to
inﬂiximab, adalimumab and etanercept, each one added to MTX
in patients with suboptimal response to MTX monotherapy.
Therefore, we recommend the use of leﬂunomide for patients
with refractory RA with suboptimal response to MTX, before
using a biological agent.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyal-
gia syndrome (FM) among the adult population in the general
population, in Germany, using the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ) and
American College of Rheumatology (ACR) classiﬁcation criteria.
METHODS: Every patients going to visit the rheumatologist in
Munchen hospital during a 30-days period, were interviewed
using the validated LFESSQ (4 items) with two additional ques-
tions on fatigue (LFESSQ 6 items), and examined to conﬁrm the
diagnostic of FM using ACR classiﬁcation criteria. The screening
questionnaire was also administered to a representative commu-
nity sample more than 15 years old, selected by the quota
method. The prevalence of FM was estimated in the general
population, applying the predictive positive value observed in
rheumatology consultation, to the positive screens, RESULTS:
A total of 52.6% patients interviewed in the rheumatology
department were screened positive for chronic widespread pain
(LFESSQ 4), 42.7% for widespread pain and fatigue (LFESSQ 6),
16.4%[15.8–16.9] were conﬁrmed FM cases. Based on positive
screens for chronic widespread pain and LFESSQ 4, the preva-
lence of FM in general population, is 5.8 % (95% IC: [4.3–7.2];
7.5% in females and in 3.8% males respectively). If fatigue is
added, the prevalence is 3.2 % (95% IC: [2.1–4.3] ; 3.9% in
females and 2.5% in males respectively). Prevalence rises with
age until the age group 75–84 years old. FM sufferers are females
wit an average age of 53.5 years old (SD: 12.4). CONCLU-
SIONS: Our ﬁndings are slightly higher than those obtained in
our study in France, Spain and Portugal, and those published in
Canada, US or Spain, probably due to the different methodolo-
gies and populations used. Symptoms of pain as fatigue must be
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